Severe hypocalcemia following denosumab injection in patient with chronic kidney disease
Nefrologia. 2016 Jul-Aug;36(4):446-8.
doi: 10.1016/j.nefro.2016.02.007.
Epub 2016 Mar 21.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Endocrinología, Hospital Universitario Marqués de Valdecilla, Santander (Cantabria), España.
- 2 Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander (Cantabria), España.
- 3 Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander (Cantabria), España. Electronic address: nefffg@humv.es.
No abstract available
MeSH terms
-
Adrenal Cortex Hormones / adverse effects
-
Adrenal Cortex Hormones / therapeutic use
-
Adult
-
Calcitriol / therapeutic use
-
Calcium Carbonate / therapeutic use
-
Chelating Agents / therapeutic use
-
Cholecalciferol / therapeutic use
-
Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy
-
Chronic Kidney Disease-Mineral and Bone Disorder / etiology
-
Denosumab / administration & dosage
-
Denosumab / adverse effects*
-
Glomerulosclerosis, Focal Segmental / complications
-
Glomerulosclerosis, Focal Segmental / therapy
-
Humans
-
Hypocalcemia / chemically induced*
-
Male
-
Nephrotic Syndrome / drug therapy
-
Nephrotic Syndrome / etiology
-
Osteoporosis / chemically induced
-
Osteoporosis / drug therapy
-
Renal Insufficiency, Chronic / drug therapy*
-
Renal Insufficiency, Chronic / etiology
-
Sevelamer / therapeutic use
Substances
-
Adrenal Cortex Hormones
-
Chelating Agents
-
Cholecalciferol
-
Denosumab
-
Sevelamer
-
Calcitriol
-
Calcium Carbonate